CRBU · CIK 0001619856
Caribou Biosciences, Inc.
What Caribou Biosciences, Inc. owns has not been researched yet. This page is its ownership register, who holds it, and the absence of holdings below means nobody has looked rather than that there is nothing to find.
Caribou Biosciences, Inc. - Profile
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
- Listed on
- Nasdaq
- Employees
- 97stated 2026
- Incorporated in
- Delaware
- Financial year ends
- 31 December
Source
Address, industry classification, listing and incorporation come from Caribou Biosciences, Inc.'s own SEC filer record, so the industry is the SEC's dry classification rather than a marketing label. The headcount is the figure the sources below state for 2026. The description was written for this site in August 2026 from Caribou Biosciences, Inc. Form 10-K for fiscal year 2025, Caribou Biosciences, Inc. Form 10-Q for the quarter ended 30 June 2026 and Caribou Biosciences, Inc. Form 8-K dated 13 August 2026, Exhibit 99.1 (second quarter 2026 results), not taken from any single article.
Share price
CRBU
Description
Caribou Biosciences, Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company in Berkeley, California that develops off-the-shelf allogeneic CAR-T cell therapies. Its platform uses chRDNA guides, hybrid RNA-DNA in place of the all-RNA guides of first-generation CRISPR-Cas9 and Cas12a: the DNA lowers affinity for near-match sites, yielding minor to no detectable off-target editing while supporting multiplex knockouts and site-specific insertions. An April 2025 pipeline prioritization left two candidates: it discontinued the CB-012 AMpLify trial, the GALLOP lupus trial before first dosing and preclinical research, and cut 47 jobs (about 32% of the workforce). Vispacabtagene regedleucel (vispa-cel, formerly CB-010) is an anti-CD19 CAR-T with a PD-1 knockout: the ANTLER phase 1 trial treated 85 patients, and on 7 May 2026 Caribou announced FDA alignment on ANTLER-3, a planned pivotal phase 3 in roughly 250 second-line large B cell lymphoma patients. CB-011, anti-BCMA with a B2M knockout and a B2M-HLA-E fusion for immune cloaking, is enrolling dose expansion in the CaMMouflage phase 1, with initial data expected in the second half of 2026. Net loss was $148.1 million in 2025 and $49.4 million in the first half of 2026. Cash and marketable securities were $113.8 million at 30 June 2026, guided to fund operations to the end of 2027, with ANTLER-3 not yet fully funded.
Who owns Caribou Biosciences, Inc..
Nothing recorded on this side. That is a sourced finding rather than a gap where the research notes say so: see the notes below.
Select a row or a slice for its provenance: the filing it came from, when it was measured, and the arithmetic behind it if it was modelled.
The full register, from 13F filings
The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 131 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.
131 managers reported a position, together holding 37.8m shares, or 38.1% of the company. The 40 largest are listed. Percentages are of the 99.2m shares outstanding at 30 Apr 2026, the count in force when this quarter was measured rather than the count today.
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
What a reader needs to know to read these numbers
- Added 27 Aug 2026 by scripts/promote_discovered.py. This company reached the site because a covered investor holds it, not because an index listed it: it was a position in a portfolio here with no page of its own. The match was proved by requiring the register built for this CIK to contain the same CUSIP the portfolio held.
- Discovered at CUSIP 142038108, held by ameriprise, bank-of-america, blackrock, bny-mellon, citigroup, fidelity-fmr, geode, goldman-sachs, invesco, jpmorgan, morgan-stanley, northern-trust, pfizer, pnc, prudential-financial, raymond-james, state-street, us-bancorp, vanguard, wells-fargo.
- Holdings are NOT researched. The empty holdings list means nobody has looked at what this company owns, not that it owns nothing, and the page says so.
- Shares outstanding and market cap are null rather than guessed. Neither was captured on the dated sweep that carries every other company here.
Looked for, not found
Recorded rather than filled in. Each of these is a place where a number could have been invented and was not.
- Shares outstanding.
- Market capitalisation.